Orchid Pharma Peer Comparison

Orchid Pharma Ltd. demonstrates strong growth metrics compared to its peers, particularly in revenue growth and EPS. However, it has a relatively high PE ratio, indicating potential overvaluation concerns. Companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. stand out for their strong profitability and attractive valuations, making them potential value picks. Overall, Orchid Pharma has a competitive edge in growth but needs to address valuation concerns.

• • Orchid Pharma shows robust revenue growth (YoY) at 23.05%.
• • Cipla and Dr. Reddy's are the most attractive based on profitability and valuation.
• • Divi's Laboratories has the highest PE and is considered overvalued.
• • Mankind Pharma has impressive growth metrics but is not as profitable as peers.

• • Cipla Ltd.: Strong profitability metrics and attractive valuation (PE 23.73).
• • Dr. Reddy's Laboratories Ltd.: Top ROE and ROCE with excellent growth trajectory and low PE (15.50).